You are here: Industry Insights > immunotherapy

News List

Werewolf Therapeutics Appoints Mike Sherman to its Board of Directors firstwordpharma
May 31, 2021
Werewolf Therapeutics, Inc. today announced the appointment of Mike Sherman, chief executive officer of Chimerix, Inc., as a member of its board of directors.
Personalised cancer vaccine safe and potentially beneficial to patients europeanpharmaceuticalreview
April 12, 2021
Mount Sinai researchers reveal that, in a Phase I trial, their personalised cancer vaccines targeting cancer neoantigens showed some early signs of potential benefit.
Immunotherapy vaccine shows promise in prostate cancer patients europeanpharmaceuticalreview
March 31, 2021
The multi-targeted hAd5 immunotherapy vaccine was found to be safe and showed initial signs of efficacy in patients with advanced metastatic castration-resistant prostate cancer.
GeoVax Expands Intellectual Property Portfolio americanpharmaceuticalreview
March 09, 2021
GeoVax Labs announced the filing of two additional patent applications important to the Company’s key focus on vaccines against SARS-CoV-2 (COVID-19) and cancer immunotherapies.
Radiotherapy responses may be improved with targeted immunotherapy, study suggests pharmatimes
March 08, 2021
A new study suggests that targeted immunotherapy could make cancers that are resistant to radiotherapy more responsive to treatment.
Onward Therapeutics Makes a Strategic Investment in EMERCell for Their NK Cell Technology for Immunotherapy prnasia
February 22, 2021
Onward Therapeutics SA (Onward) announced today the execution of a strategic investment in EMERCell SAS, Montpellier, France, a company that has developed a platform technology to produce off-the-shelf natural killer (NK) cells.
FibroGenesis Reports Positive Data in Pancreatic, Breast Cancer Using Fibroblast-Based Immunotherapy americanpharmaceuticalreview
February 20, 2021
FibroGenesis announced new data supporting utilizing its fibroblast-based immunotherapy for successful inhibition and induction of regression in preclinical models of breast cancer and pancreatic cancer.
AstraZeneca and UCL to collaborate on two immuno-oncology projects pharmatimes
February 04, 2021
British drugmaker and researchers from the UCL Division of Infection & Immunity will collaborate on two projects which will aim to contribute to the development of new cancer treatments.
Gilead, Gritstone Enter Vax Platform Pact for HIV Cure contractpharma
February 02, 2021
Aims to develop HIV-specific vaccine using Gritstone’s prime-boost vaccine platform with antigens developed by Gilead.
ImmunityBio and NantKwest announce merger expresspharma
December 22, 2020
Merged entity brings together 11 Phase II / III clinical trials across oncology and infectious disease that use combined immunotherapy platforms.

Previous page 1 2 3 4 5 6 7 8 9 10 11 12 Next page